Xeris Biopharma Holdings, Inc.XERSNASDAQ
Loading
Cost of Revenue Over TimeExpanding
Percentile Rank100
3Y CAGR+33.1%
5Y CAGR+41.8%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+33.1%/yr
vs +381.8%/yr prior
5Y CAGR
+41.8%/yr
Recent deceleration
Acceleration
-348.7pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
5.7x
Strong expansion
Streak
8 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $53.41M | +45.0% |
| 2024 | $36.83M | +28.6% |
| 2023 | $28.64M | +26.6% |
| 2022 | $22.63M | +70.0% |
| 2021 | $13.32M | +42.8% |
| 2020 | $9.33M | +481.9% |
| 2019 | $1.60M | +3716.7% |
| 2018 | $42000.00 | +950.0% |
| 2017 | $4000.00 | -50.0% |
| 2016 | $8000.00 | - |